![Topical 5-fluorouracil and Imiquimod Efficacy in Basal and Squamous Cell Carcinomas - Skin Cancer and Reconstructive Surgery Center Topical 5-fluorouracil and Imiquimod Efficacy in Basal and Squamous Cell Carcinomas - Skin Cancer and Reconstructive Surgery Center](https://scarscenter.com/wp-content/uploads/2017/12/SCARS-Center-topical-5-fluorouracil-efficacy-in-basal-cell-carcinoma-skin-cancer1.jpg)
Topical 5-fluorouracil and Imiquimod Efficacy in Basal and Squamous Cell Carcinomas - Skin Cancer and Reconstructive Surgery Center
![How to use fluorouracil and imiquimod as treatments for non melanoma skin cancer in a general practice setting - Best Practice Advocacy Centre New Zealand How to use fluorouracil and imiquimod as treatments for non melanoma skin cancer in a general practice setting - Best Practice Advocacy Centre New Zealand](https://bpac.org.nz/2017/img/imiquimod-aks-mild.jpg)
How to use fluorouracil and imiquimod as treatments for non melanoma skin cancer in a general practice setting - Best Practice Advocacy Centre New Zealand
![Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study | SpringerLink Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00417-007-0561-1/MediaObjects/417_2007_561_Fig2_HTML.jpg)
Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study | SpringerLink
![Imiquimod Induces Sustained Remission of Actinic Damage: A Case Report Spanning One Decade of Observation | MDedge Dermatology Imiquimod Induces Sustained Remission of Actinic Damage: A Case Report Spanning One Decade of Observation | MDedge Dermatology](https://cdn.mdedge.com/files/s3fs-public/images/RTEmagicC_CT095020020-e_Fig1.jpg.jpg)
Imiquimod Induces Sustained Remission of Actinic Damage: A Case Report Spanning One Decade of Observation | MDedge Dermatology
![Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial - The Lancet Oncology Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/2021742740/2041575949/gr1.gif)
Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial - The Lancet Oncology
![Imiquimod Induces Sustained Remission of Actinic Damage: A Case Report Spanning One Decade of Observation | MDedge Dermatology Imiquimod Induces Sustained Remission of Actinic Damage: A Case Report Spanning One Decade of Observation | MDedge Dermatology](https://cdn.mdedge.com/files/s3fs-public/images/RTEmagicC_CT095020020-e_Fig2B.jpg.jpg)
Imiquimod Induces Sustained Remission of Actinic Damage: A Case Report Spanning One Decade of Observation | MDedge Dermatology
![PDF] Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up. | Semantic Scholar PDF] Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a97aa572bcea3616280d8808a05abced1fe6db03/2-Figure2-1.png)
PDF] Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up. | Semantic Scholar
![Treatment of Basal Cell Carcinoma with Curettage Followed by Imiquimod 3.75% Cream – JCAD | The Journal of Clinical and Aesthetic Dermatology Treatment of Basal Cell Carcinoma with Curettage Followed by Imiquimod 3.75% Cream – JCAD | The Journal of Clinical and Aesthetic Dermatology](https://jcadonline.com/wp-content/uploads/zeichnerfig3.jpg)
Treatment of Basal Cell Carcinoma with Curettage Followed by Imiquimod 3.75% Cream – JCAD | The Journal of Clinical and Aesthetic Dermatology
![Imiquimod 5% as Adjuvant Therapy for Incompletely Excised Infiltrative Nodular Basal Cell Carcinoma and Dermoscopy to Monitor Treatment Response | SpringerLink Imiquimod 5% as Adjuvant Therapy for Incompletely Excised Infiltrative Nodular Basal Cell Carcinoma and Dermoscopy to Monitor Treatment Response | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs13555-015-0088-z/MediaObjects/13555_2015_88_Fig7_HTML.jpg)
Imiquimod 5% as Adjuvant Therapy for Incompletely Excised Infiltrative Nodular Basal Cell Carcinoma and Dermoscopy to Monitor Treatment Response | SpringerLink
![Successful treatment of two invasive squamous cell carcinomas with topical 5% imiquimod cream in elderly patients. | Semantic Scholar Successful treatment of two invasive squamous cell carcinomas with topical 5% imiquimod cream in elderly patients. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/6dffa3c50c04064290051e83dbf4e0acaabde423/1-Figure1-1.png)
Successful treatment of two invasive squamous cell carcinomas with topical 5% imiquimod cream in elderly patients. | Semantic Scholar
![Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study | SpringerLink Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00417-007-0561-1/MediaObjects/417_2007_561_Fig1_HTML.jpg)
Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study | SpringerLink
![John Libbey Eurotext - European Journal of Dermatology - Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study John Libbey Eurotext - European Journal of Dermatology - Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study](http://www.jle.com/e-docs/00/04/10/A7/texte_alt_jleejd00120_gr3.jpg)
John Libbey Eurotext - European Journal of Dermatology - Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study
![Imiquimod cream efficacy in the treatment of periocular nodular basal cell carcinoma: a non-randomized trial | BMC Ophthalmology | Full Text Imiquimod cream efficacy in the treatment of periocular nodular basal cell carcinoma: a non-randomized trial | BMC Ophthalmology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12886-015-0024-0/MediaObjects/12886_2015_24_Fig2_HTML.gif)
Imiquimod cream efficacy in the treatment of periocular nodular basal cell carcinoma: a non-randomized trial | BMC Ophthalmology | Full Text
![Treatment of Basal Cell Carcinoma with Curettage Followed by Imiquimod 3.75% Cream – JCAD | The Journal of Clinical and Aesthetic Dermatology Treatment of Basal Cell Carcinoma with Curettage Followed by Imiquimod 3.75% Cream – JCAD | The Journal of Clinical and Aesthetic Dermatology](https://jcadonline.com/wp-content/uploads/zeichnerfig5.jpg)